Sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC): updated efficacy and safety results and further analysis of prognostic factors

被引：15
|
作者：
Motzer, R. J. [1 ]
Michaelson, M. D. [2 ]
Hutson, T. E. [3 ]
Tomczak, P. [4 ]
Bukowski, R. M. [5 ]
Rixe, O. [6 ]
Negrier, S. [7 ]
Kim, S. T. [8 ]
Chen, I.
Figlin, R. A. [9 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Genitourinary Oncol Serv, New York, NY USA
[2] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA
[3] Baylor Sammons Canc Ctr Texas Oncol, Dallas, TX USA
[4] Klin Onkol Oddzial Chem, Poznan, Poland
[5] Cleveland Clin Taussig Canc Ctr, Cleveland, OH USA
[6] Hop La Pitie Salpetriere, Paris, France
[7] Ctr Leon Berard, Lyon, France
[8] Pfizer Inc, La Jolla, CA USA
[9] City Hope Comprehens Canc Ctr, Los Angeles, CA USA
来源：
EJC SUPPLEMENTS | 2007年 / 5卷 / 04期
关键词：
D O I：
10.1016/S1359-6349(07)71140-0
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4509
引用
收藏
页码：301 / 301
页数：1
相关论文
共 50 条
  • [1] Sunitinib versus interferon-alfa (IFN-α) as first-line treatment of metastatic renal cell carcinoma (mRCC): Updated results and analysis of prognostic factors
    Motzer, R. J.
    Figlin, R. A.
    Hutson, T. E.
    Tomczak, P.
    Bukowski, R. M.
    Rixe, O.
    Bjarnason, G. A.
    Kim, S. T.
    Chen, I.
    Michaelson, D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [2] OVERALL SURVIVAL WITH SUNITINIB VERSUS INTERFERON (IFN)-ALFA AS FIRST-LINE TREATMENT OF METASTATIC RENAL CELL CARCINOMA (MRCC)
    Negrier, S.
    Figlin, R. A.
    Hutson, T. E.
    Tomczak, P.
    Michaelson, M. D.
    Bukowski, R. M.
    Huang, X.
    Kim, S. T.
    Chen, I.
    Motzer, R. J.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 : 190 - 190
  • [3] Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC)
    Figlin, R. A.
    Hutson, T. E.
    Tomczak, P.
    Michaelson, M. D.
    Bukowski, R. M.
    Negrier, S.
    Huang, X.
    Kim, S. T.
    Chen, I.
    Motzer, R. J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [4] OVERALL SURVIVAL WITH SUNITINIB VERSUS INTERFERON-ALFA (IFN-□) AS FIRST-LINE TREATMENT FOR METASTATIC RENAL CELL CARCINOMA (MRCC)
    Szczylik, C.
    Negrier, S.
    Oudard, S.
    Figlin, R. A.
    Hutson, T. E.
    Tomczak, P.
    Michaelson, M. D.
    Bukowski, R. M.
    Huang, X.
    Kim, S. T.
    Chen, I
    Motzer, R. J.
    [J]. EUROPEAN UROLOGY SUPPLEMENTS, 2009, 8 (04) : 182 - 182
  • [5] Sunitinib versus interferon-α for first-line treatment of metastatic renal cell carcinoma:: Updated results and further prognostic factor analyses
    Gruenwald, V.
    Eberhardt, W.
    Ringhoffer, M.
    Jakse, G.
    Motzer, R. J.
    [J]. ONKOLOGIE, 2008, 31 : 179 - 179
  • [6] Economic evaluations of sunitinib versus interferon-alfa (IFN-α) in first-line metastatic renal cell carcinoma (mRCC)
    Remak, E.
    Mullins, C. D.
    Akobundu, E.
    Charbonneau, C.
    Woodruff, K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [7] Sunitinib as first-line treatment for metastatic renal cell carcinoma (MRCC): Updated results and analysis of prognostic factors from a phase III randomised trial
    Oudard, S.
    Motzer, R. J.
    Michaelson, M. D.
    Hutson, T. E.
    Tomczak, P.
    Bukowski, R. M.
    Rixie, O.
    Negrier, S.
    Kim, S. T.
    Chen, J.
    Figlin, R. A.
    [J]. EUROPEAN UROLOGY SUPPLEMENTS, 2008, 7 (03) : 245 - 245
  • [8] Economic evaluation of sunitinib vs. interferon-alfa (IFN-alfa) in first-line treatment of Metastatic Renal Cell Carcinoma (MRCC) in Colombia
    Godoy, J., I
    Cardona, A. F.
    Alvis, N.
    Arango, C. H.
    Romero, M.
    Spath, A.
    Ramirez, P.
    Caceres, H. A.
    Quijano, M. F.
    [J]. VALUE IN HEALTH, 2008, 11 (03) : A100 - A100
  • [9] Quality of life (QOL) with sunitinib versus interferon-alfa (IFN-α) as first-line therapy in patients with metastatic renal cell carcinoma (mRCC): Final results
    Cella, D.
    Michaelson, M. D.
    Cappelleri, J. C.
    Bushmakin, A. G.
    Charbonneau, C.
    Kim, S. T.
    Li, J. Z.
    Motzer, R. J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [10] Economic evaluation of sunitinib vs. interferon-alfa (IFN-α) in first-line metastatic renal cell carcinoma (mRCC)
    Negrier, S.
    Remak, E.
    Brown, R.
    Kim, S. T.
    Charbonneau, C.
    Motzer, R. J.
    [J]. EJC SUPPLEMENTS, 2007, 5 (04): : 303 - 303
12345